CJC-1295

CJC 1295 is a synthetic analogue of the growth hormone-releasing hormone (GHRH). GHRH stimulates the anterior pituitary to produce and release growth hormone (GH) into the bloodstream. GH, in turn, stimulates the secretion of insulin-like growth factor (IGF-1) from the liver.

One study has shown that a single administration of CJC-1295 could potentially produce 2- to 10-fold increases in plasma GH concentrations among healthy adults. Furthermore, multiple CJC-1295 doses resulted in mean IGF-1 levels potentially remaining above baseline for up to 28 days.

CJC-1295 is a synthetically modified form of GHRH. This peptide hormone potentially stimulates the GHRH to increase the secretion of growth hormones from the pituitary gland. CJC-1295 has also been shown to have the potential ability to increase serum IGF-1 levels in the bloodstream. It may also treat GH deficiency.

CJC-1295 has been proven to have a greater half-life and bioavailability than GHRH. This is due to the addition of drug affinity complex (DAC) to this peptide’s chain. This binding extends CJC 1295’s half-life, potentially resulting in a prolonged duration of action in several animal species.